Skip to main content

Table 2 Frequency and incidence of events in the study population (n = 5180)

From: Safety of cilostazol in peripheral artery disease: a cohort from a primary healthcare electronic database

   Risk at 5 years    
Outcomes N (%) CI95% HR CI95% p valuea
Gastrointestinal haemorrhage
 Cilostazol 35 1.2 0.8–1.6 1.10 0.7–1.8 0.711
 Pentoxifylline 31 1.1 0.7–1.4    
Cerebral haemorrhage
 Cilostazol 23 0.8 0.5–1.1 0.79 0.5–1.4 0.392
 Pentoxifylline 30 1.0 0.7–1.4    
Other haemorrhages
 Cilostazol 92 3.2 2.5–3.8 0.83 0.6–1.2 0.267
 Pentoxifylline 115 4.0 3.2–4.7    
Any haemorrhage
 Cilostazol 115 4.0 3.2–4.7 0.82 0.6–1.1 0.119
 Pentoxifylline 143 4.9 4.1–5.7    
CAD
 Cilostazol 287 9.9 8.8–11.0 0.94 0.8–1.1 0.433
 Pentoxifylline 305 10.5 9.4–11.6    
Stroke
 Cilostazol 161 5.5 4.7–6.4 0.94 0.8–1.2 0.564
 Pentoxifylline 171 5.9 5.0–6.7    
AF
 Cilostazol 194 6.7 5.8–7.6 1.02 0.8–1.2 0.857
 Pentoxifylline 190 6.5 5.6–7.4    
Other arrhythmias
 Cilostazol 89 3.1 2.4–3.7 1.14 0.8–1.5 0.392
 Pentoxifylline 78 2.7 2.1–3.3    
  1. CI 95% Confidence Interval with 95%, HR hazard ratio, CAD coronary artery disease, AF atrial fibrillation
  2. ap-value computed using univariate Cox regression with robust standard errors by clusters (pairs)
  3. Significant p-values are in boldface